Neurogene Inc. (NASDAQ:NGNE) Expected to Earn Q2 2024 Earnings of ($1.19) Per Share

Neurogene Inc. (NASDAQ:NGNE) – Equities research analysts at Leerink Partnrs issued their Q2 2024 earnings estimates for shares of Neurogene in a note issued to investors on Monday, April 29th. Leerink Partnrs analyst M. Foroohar expects that the company will earn ($1.19) per share for the quarter. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($3.98) per share. Leerink Partnrs also issued estimates for Neurogene’s Q3 2024 earnings at ($1.22) EPS, Q4 2024 earnings at ($1.23) EPS, FY2024 earnings at ($4.82) EPS, FY2025 earnings at ($4.43) EPS and FY2026 earnings at ($5.04) EPS.

Several other equities analysts have also issued reports on NGNE. William Blair assumed coverage on Neurogene in a report on Thursday, March 21st. They issued an “outperform” rating and a $61.00 target price for the company. SVB Leerink initiated coverage on Neurogene in a research note on Monday, April 29th. They issued an “outperform” rating and a $46.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Neurogene in a research note on Friday. Finally, Stifel Nicolaus began coverage on shares of Neurogene in a report on Friday, January 5th. They issued a “buy” rating and a $31.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Neurogene presently has a consensus rating of “Buy” and an average price target of $48.25.

Neurogene Stock Up 3.5 %

Shares of NGNE stock opened at $36.63 on Thursday. The company has a market cap of $471.43 million, a P/E ratio of -2.94 and a beta of 1.36. Neurogene has a 52-week low of $12.20 and a 52-week high of $53.00. The stock has a 50-day moving average price of $38.19.

Institutional Trading of Neurogene

A number of large investors have recently bought and sold shares of the company. BML Capital Management LLC bought a new position in shares of Neurogene during the 4th quarter worth $478,000. Privium Fund Management UK Ltd purchased a new stake in Neurogene during the first quarter valued at about $274,000. Great Point Partners LLC bought a new position in Neurogene during the fourth quarter worth about $19,268,000. Finally, Avidity Partners Management LP purchased a new position in shares of Neurogene in the fourth quarter worth about $9,036,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.